Taking people in ItalyNo phase
Observes eptinezumab for migraine in everyday real-life care
Studies how eptinezumab works and is tolerated in adults with migraine.
Key facts
- Who runs it
- IRCCS San Raffaele Roma
- Where
- Roma, ItalySee the site
- Trial code
- Registry title
- EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 1 Jan 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution
- Record updated
- 1 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine, either frequent episodic migraine or chronic migraine, to study eptinezumab in real-life use.
- Age
- 18 to 75 years
- Sex
- Men and women can join.
- Disease stage
- High-frequency episodic migraine: at least 8 days per month of disabling migraine in the past 3 months. Or chronic migraine, as defined by the ICHD-III criteria.
- Earlier treatment
- People currently treated with other mAbs cannot join.
Main reasons for not taking part
- Other headaches different than migraine
- Known intolerance to eptinezumab or its excipients
- Current treatment with other mAbs
- Vascular disease or Raynaud
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age between 18 and 75 years
- Males and females
- Willingness to sign the informed consent
- High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months
- Chronic migraine, according to the ICHD-III criteria
Who cannot take part
- Current treatment with other mAbs
- Vascular disease or Raynaud
- Other headaches different than migraine
- Known intolerance to eptinezumab or eccipients
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in Italy
- IRCCS San Raffaele RomaRoma, ItalyContact: Piero Barbanti, MD, PhDTaking people
About the trial
What the trial wants to find out
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Treatments tested
- Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)
- Plain-language title
- Observes eptinezumab for migraine in everyday real-life careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05570149, who can take part
- Publications
- Record updated
- 1 May 2025